Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | DPYD | Q12882 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798548 | 0.87 | ALDH1A1 (0.36) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL18640389 | 0.83 | GAA (0.44) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL16893950 | 0.81 | GAA (0.54) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL7206108 | 0.81 | CYP3A4 (0.33) | GAALMNASMN1; SMN2CYP3A4 | |
| Cytosine SCHEMBL28088394 | 0.81 | TSHR (0.33) | GAADPYDALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28917975 | 0.80 | ATAD2 (0.40) | GAAATAD2 | |
| SCHEMBL28699194 | 0.79 | GAA (0.44) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL27500671 | 0.79 | ALDH1A1 (0.44) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL5059885 | 0.79 | GAA (0.40) | GAADPYDALDH1A1LMNAMAPT | |
| SCHEMBL1546530 | 0.77 | GAA (0.41) | GAADPYDALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23120 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-12577554-B2 | Methods for purification of messenger RNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-12552858-B2 | Methods and compositions for delivering mRNA coded antibodies | TRANSLATE BIO, INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4659246-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | Atlas Data Storage, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250368986-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | ATLAS DATA STORAGE INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025137576-A1 | MULTIPLE SPECIFIC ANTIBODIES TARGETING CD19, CD20, AND/OR CD47 | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| US-20070212697-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2007-09-13 | — | — | US | claimed |
| EP-1308511-A1 | Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature. | Mermaid Pharmaceuticals GmbH (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-1295130-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2003-03-26 | — | — | EP | claimed |
| JP-2002531470-A | — | — | 2002-09-24 | — | — | JP | claimed |
| EP-1163374-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | Syntrix Biochip, Inc. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2001070776-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2000033084-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | SYNTRIX BIOCHIP, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| US-5998596-A | Inhibition of protein kinase activity by aptameric action of oligonucleotides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| US-5486603-A | Oligonucleotide having enhanced binding affinity | GILEAD SCIENCES, INC. (US) | 1996-01-23 | — | — | US | claimed |